Cabamiquine for malaria, falciparum

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Aug 2017: Trial registered, NCT03261401
  2. 15 Sep 2017: Trial started, NCT03261401

The trials

NCT03261401: First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants

State
Completed
Phase
Phase 1
People
88 taking part
Started
15 Sep 2017
Primary completion
14 Jun 2019
Arms
Part A: Cohort 1 SAD: M5717 50 mg, Part A: Cohort 2 SAD: M5717 100 mg, Part A: Cohort 3 SAD: M5717 200 mg, Part A: Cohort 4 SAD: M5717 400 mg, Part A: Cohort 5 SAD: M5717 600 mg, Part A: Cohort 6 SAD: M5717 1000 mg, Part A: Cohort 7 SAD: M5717 1250 mg, Part A: Cohort 8 SAD: M5717 1800 mg, Part A: Cohort 9 SAD: M5717 2100 mg, Part C: Challenge Cohort 2 M5717 150 mg, Part C: Challenge Cohort 1 M5717 400 mg, Part C: Challenge Cohort 3 M5717 800 mg
Results
Posted on the registry
Papers
doi:10.1016/s1473-3099(21)00252-8
  1. 25 Aug 2017: Trial registered
  2. 15 Sep 2017: Trial started
  3. 14 Jun 2019: Trial completed
  4. 16 Oct 2023: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.